A small phase I dose-finding trial in Zambia and Kenya selected 3 mg/kg per infusion as the maximum tolerated dose of sevuparin for further investigation in children hospitalized with severe malaria. Across 20 evaluable participants, dose-limiting coagulation abnormalities occurred at higher doses (4–6 mg/kg) but not at 3 mg/kg. The trial was designed for safety and tolerability rather than efficacy, and it remains unclear whether sevuparin improves survival or other clinical outcomes. Still, the dosing decision refines a key step for downstream trials because standard heparin analogs have historically shown inconsistent malaria results. From a biotech standpoint, the study narrows the clinical development runway for a host-pathology-targeting adjunct aimed at parasite sequestration in microvasculature—an approach that will now need efficacy confirmation in controlled studies.